Most recently, it was found that cancer cell lines that overexpress MDM2 show attenuated levels of γH2AX, a key mediator of DNA damage signaling, as a result of VP-16 treatment, while treatment with neocarzinostatin (a genotoxic anti-cancer drug) did not result in a noticeable difference in γH2AX [11]. The gene discussed is MDM2; the disease is cancer.